Compound: TRIMETAZIDINE
SMILES: O(c1c(OC)c(ccc1OC)CN2CCNCC2)C
InChIKey: UHWVSEOVJBQKBE-UHFFFAOYSA-N
Synonyms: TRIMETAZIDINE, 5011-34-7, 1-[(2,3,4-trimethoxyphenyl)methyl]piperazine, Trimetazidina, Trimetazidinum, Dilatan, N9A0A0R9S8, Piperazine, 1-((2,3,4-trimethoxyphenyl)methyl)-, DTXSID2048531, Piperazine, 1-[(2,3,4-trimethoxyphenyl)methyl]-, 1-((2,3,4-trimethoxyphenyl)methyl)piperazine, Vastarel MR, RefChem:191732, DTXCID9027998, C01EB15, 225-690-2, 1-(2,3,4-Trimethoxybenzyl)piperazine, MFCD00868263, 1-(2,3,4-Trimethoxy-benzyl)-piperazine, Preductal, Trimetazidine (INN), Trimetazidine 2HCl, TRIMETAZIDINE [INN], MLS001240268, Trimetazidinum [INN-Latin], Trimetazidina [INN-Spanish], Trimetazidine [INN:BAN:DCF], 1,2,3-trimethoxy-4-(piperazinylmethyl)benzene, NCGC00016697-01, SMR000674573, EINECS 225-690-2, CAS-13171-25-0, UNII-N9A0A0R9S8, Vasorel, Preductal MB, Dilatan (TN), Trimetazidine (NIST), BAS 06612844, Trimetazidine (Standard), Prestwick0_000549, Prestwick1_000549, Prestwick2_000549, Prestwick3_000549, TRIMETAZIDINE [MI], Oprea1_279550, Piperazine,1-[(2,3,4-trimethoxyphenyl)methyl]-, BSPBio_000597, MLS001331735, SCHEMBL230374, SPBio_002518, TRIMETAZIDINE [WHO-DD], BPBio1_000657, CHEMBL203266, HY-B0968AR, orb3027362, SCHEMBL8104266, SCHEMBL11846840, SCHEMBL29375563, BDBM80613, CHEBI:94789, cid_9926449, HY-B0968A, HMS2230L07, HMS3374D04, HMS5085F07, FAA01134, BBL013084, EBC-03819, s5779, SBB007020, STK315643, AKOS000308094, 4-(2,3,4-Trimethoxybenzyl)piperazine, DB09069, SB75326, 1-(2,3,4-trimethoxy benzyl)piperazine, NCGC00016697-02, IT106475, SMR000814701, 1-(2,3,4-trimethoxyphenyl)methylpiperazine, 1-(2,3,4-trimethoxyphenylmethyl)piperazine, DB-051731, 1-(2,3,4-Trimethoxybenzyl)piperazine 2HCl, CS-0099250, NS00005746, ST45134749, EN300-14439, D08642, G12771, F029299, Q674703, 1-(2,3,4-trimethoxybenzyl)piperazine;hydrochloride, 1-[2,3,4-trimethoxybenzyl] piperazine dihydrochloride, BRD-K88366685-300-03-7, BRD-K88366685-300-04-5, BRD-K88366685-300-06-0, Z99601262, 1-[(2,3,4-trimethoxyphenyl)methyl]piperazine;hydrochloride, 127881-54-3
Theoretical properties:
molecular_formula: C14H22N2O3
molecular_weight: 266.34 g/mol
exact_mass: 266.16304257 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 1
hydrogen_bond_acceptor_count: 5
rotatable_bond_count: 5
heavy_atom_count: 19
topological_polar_surface_area: 43 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
Descriptions:
pubchem: 1-[(2,3,4-trimethoxyphenyl)methyl]piperazine is an aromatic amine.
chembl: TRIMETAZIDINE is a small molecule listed in the ChEMBL database and has reached clinical trial phase 3.0.
wikipedia: Trimetazidine (IUPAC: 1-(2,3,4-trimethoxybenzyl)piperazine) is a drug used in the treatment of angina pectoris, a condition characterized by chest pain due to reduced blood flow to the heart. Developed and first marketed by Laboratoires Servier (France), it is described as the first cytoprotective anti-ischemic agent. Trimetazidine is an antianginal metabolic drug of the fatty acid oxidation inhibitor class; it shifts cardiac energy metabolism from fatty acid utilization toward glucose oxidation, thereby improving the efficiency of energy production in ischemic conditions.
The drug has also become controversial as a performance-enhancing drug, with multiple doping scandals linked to its use at successive Olympic Games.